vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $270.4M, roughly 1.3× Enhabit, Inc.). AdvanSix Inc. runs the higher net margin — -0.8% vs -14.3%, a 13.5% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 4.7%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $3.3M). Over the past eight quarters, AdvanSix Inc.'s revenue compounded faster (3.4% CAGR vs 1.5%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
ASIX vs EHAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $270.4M |
| Net Profit | $-2.8M | $-38.7M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | -12.3% |
| Net Margin | -0.8% | -14.3% |
| Revenue YoY | 9.4% | 4.7% |
| Net Profit YoY | -892.9% | 15.9% |
| EPS (diluted) | $-0.11 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $270.4M | ||
| Q3 25 | $374.5M | $263.6M | ||
| Q2 25 | $410.0M | $266.1M | ||
| Q1 25 | $377.8M | $259.9M | ||
| Q4 24 | $329.1M | $258.2M | ||
| Q3 24 | $398.2M | $253.6M | ||
| Q2 24 | $453.5M | $260.6M | ||
| Q1 24 | $336.8M | $262.4M |
| Q4 25 | $-2.8M | $-38.7M | ||
| Q3 25 | $-2.6M | $11.1M | ||
| Q2 25 | $31.4M | $5.2M | ||
| Q1 25 | $23.3M | $17.8M | ||
| Q4 24 | $352.0K | $-46.0M | ||
| Q3 24 | $22.3M | $-110.2M | ||
| Q2 24 | $38.9M | $-200.0K | ||
| Q1 24 | $-17.4M | $200.0K |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | -12.3% | ||
| Q3 25 | -0.9% | 6.4% | ||
| Q2 25 | 7.7% | 6.3% | ||
| Q1 25 | 7.7% | 6.1% | ||
| Q4 24 | -3.9% | -16.0% | ||
| Q3 24 | 7.5% | -38.6% | ||
| Q2 24 | 11.5% | 4.3% | ||
| Q1 24 | -7.0% | 4.9% |
| Q4 25 | -0.8% | -14.3% | ||
| Q3 25 | -0.7% | 4.2% | ||
| Q2 25 | 7.7% | 2.0% | ||
| Q1 25 | 6.2% | 6.8% | ||
| Q4 24 | 0.1% | -17.8% | ||
| Q3 24 | 5.6% | -43.5% | ||
| Q2 24 | 8.6% | -0.1% | ||
| Q1 24 | -5.2% | 0.1% |
| Q4 25 | $-0.11 | $-0.76 | ||
| Q3 25 | $-0.10 | $0.22 | ||
| Q2 25 | $1.15 | $0.10 | ||
| Q1 25 | $0.86 | $0.35 | ||
| Q4 24 | $0.02 | $-0.92 | ||
| Q3 24 | $0.82 | $-2.20 | ||
| Q2 24 | $1.43 | $0.00 | ||
| Q1 24 | $-0.65 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $43.6M |
| Total DebtLower is stronger | — | $426.0M |
| Stockholders' EquityBook value | $815.2M | $534.0M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $43.6M | ||
| Q3 25 | $23.7M | $56.9M | ||
| Q2 25 | $18.4M | $37.1M | ||
| Q1 25 | $8.3M | $39.5M | ||
| Q4 24 | $19.6M | $28.4M | ||
| Q3 24 | $17.3M | $45.7M | ||
| Q2 24 | $12.1M | $28.5M | ||
| Q1 24 | $20.6M | $36.5M |
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $441.5M | ||
| Q2 25 | — | $456.9M | ||
| Q1 25 | — | $467.3M | ||
| Q4 24 | — | $492.6M | ||
| Q3 24 | — | $502.9M | ||
| Q2 24 | — | $512.7M | ||
| Q1 24 | — | $526.7M |
| Q4 25 | $815.2M | $534.0M | ||
| Q3 25 | $818.2M | $566.8M | ||
| Q2 25 | $823.7M | $552.4M | ||
| Q1 25 | $794.4M | $543.2M | ||
| Q4 24 | $774.6M | $523.5M | ||
| Q3 24 | $766.4M | $566.1M | ||
| Q2 24 | $746.6M | $674.3M | ||
| Q1 24 | $713.2M | $672.3M |
| Q4 25 | $1.7B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.5B | $1.4B | ||
| Q1 24 | $1.5B | $1.4B |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $4.4M |
| Free Cash FlowOCF − Capex | $36.1M | $3.3M |
| FCF MarginFCF / Revenue | 10.0% | 1.2% |
| Capex IntensityCapex / Revenue | 7.7% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $4.4M | ||
| Q3 25 | $26.6M | $37.8M | ||
| Q2 25 | $21.1M | $10.6M | ||
| Q1 25 | $11.4M | $17.9M | ||
| Q4 24 | $64.2M | $-4.1M | ||
| Q3 24 | $57.3M | $28.4M | ||
| Q2 24 | $50.2M | $9.6M | ||
| Q1 24 | $-36.2M | $17.3M |
| Q4 25 | $36.1M | $3.3M | ||
| Q3 25 | $66.0K | $36.2M | ||
| Q2 25 | $-7.2M | $8.7M | ||
| Q1 25 | $-22.6M | $17.6M | ||
| Q4 24 | $29.8M | $-4.7M | ||
| Q3 24 | $26.8M | $27.7M | ||
| Q2 24 | $16.7M | $8.9M | ||
| Q1 24 | $-71.6M | $15.5M |
| Q4 25 | 10.0% | 1.2% | ||
| Q3 25 | 0.0% | 13.7% | ||
| Q2 25 | -1.7% | 3.3% | ||
| Q1 25 | -6.0% | 6.8% | ||
| Q4 24 | 9.1% | -1.8% | ||
| Q3 24 | 6.7% | 10.9% | ||
| Q2 24 | 3.7% | 3.4% | ||
| Q1 24 | -21.3% | 5.9% |
| Q4 25 | 7.7% | 0.4% | ||
| Q3 25 | 7.1% | 0.6% | ||
| Q2 25 | 6.9% | 0.7% | ||
| Q1 25 | 9.0% | 0.1% | ||
| Q4 24 | 10.4% | 0.2% | ||
| Q3 24 | 7.7% | 0.3% | ||
| Q2 24 | 7.4% | 0.3% | ||
| Q1 24 | 10.5% | 0.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.41× | ||
| Q2 25 | 0.67× | 2.04× | ||
| Q1 25 | 0.49× | 1.01× | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | 86.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
